ABSTRACT BACKGROUND Patients with multiple sclerosis (MS) receiving disease-
modifying therapies (DMT) show published adherence rates of 27.0% to 93.8% and …

Background The treatment landscape for multiple sclerosis (MS) is quickly evolving.
Understanding real-world treatment patterns of patients is necessary to identifying potential …

Objectives We assessed the association between hydroxychloroquine (HCQ) initiation and
risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident …

Background: Although over a dozen disease modifying treatments (DMTs) are available for
relapsing forms of multiple sclerosis (MS), treatment interruption, switching and …

Objectives To explore adherence, persistence, and treatment patterns in patients with
multiple sclerosis (MS) in Finland treated with disease‐modifying therapies (DMTs) for active …

Background Treatment switching is a common challenge and opportunity in real-world
clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated …

Background: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms
of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) …

Introduction and aim Several factors have been associated with poor adherence to disease-
modifying drugs (DMD). The aim of this study is to evaluate the adherence to DMD in people …

Background Patients with relapsing multiple sclerosis (RMS) are maintained on disease-
modifying therapy (DMT) to prevent disease progression. Reported persistence rates to …

Purpose Multiple sclerosis is a chronic, demyelinating, and degenerative disease of the
central nervous system with an immune-based pathologic origin. The present pilot study …